TwinBeech Capital’s Amicus Therapeutics FOLD Stock Holding History

TwinBeech Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,306	Closed	-$248K	–	653
2025 Q2	$248K	Sell	43,306 -58,543	-57%	-$378K	0.01%	571
2025 Q1	$831K	Buy	+101,849	New	+$943K	0.02%	511
2024 Q4	–	Sell	-229,630	Closed	-$2.45M	–	714
2024 Q3	$2.45M	Buy	229,630 +195,485	+573%	+$2.13M	0.05%	381
2024 Q2	$339K	Buy	+34,145	New	+$350K	0.01%	470
2024 Q1	–	Sell	-149,387	Closed	-$2.12M	–	664
2023 Q4	$2.12M	Buy	149,387 +61,592	+70%	+$699K	0.03%	392
2023 Q3	$1.07M	Buy	+87,795	New	+$1.13M	0.02%	486
2021 Q3	–	Sell	-82,325	Closed	-$794K	–	650
2021 Q2	$794K	Buy	+82,325	New	+$804K	0.1%	244
2021 Q1	–	Sell	-15,354	Closed	-$355K	–	520
2020 Q4	$355K	Sell	15,354 -24,300	-61%	-$497K	0.06%	342
2020 Q3	$560K	Buy	+39,654	New	+$578K	0.12%	237
2020 Q1	–	Sell	-43,103	Closed	-$420K	–	359
2019 Q4	$420K	Buy	+43,103	New	+$395K	0.12%	242

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TwinBeech Capital's FOLD Position: Q3 2025 in Review

TwinBeech Capital sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 43,306 shares — an estimated $248K sold.

TwinBeech Capital first reported a position in FOLD in Q4 2019 and held it in 10 quarters. The position peaked at $2.45M in Q3 2024. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

TwinBeech Capital reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 43,306 Amicus Therapeutics shares in Q3 2025, an estimated $248K.
TwinBeech Capital first reported a position in Amicus Therapeutics in Q4 2019 and held it in 10 quarters.
TwinBeech Capital's Amicus Therapeutics position peaked at $2.45M in Q3 2024.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.